{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:36:38Z","timestamp":1790033798443,"version":"4.0.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,12,8]],"date-time":"2014-12-08T00:00:00Z","timestamp":1417996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,12,8]],"date-time":"2014-12-08T00:00:00Z","timestamp":1417996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1038\/leu.2014.340","type":"journal-article","created":{"date-parts":[[2014,12,8]],"date-time":"2014-12-08T07:35:08Z","timestamp":1418024108000},"page":"1267-1278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Pre-clinical efficacy of combined therapy with novel \u03b2-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells"],"prefix":"10.1038","volume":"29","author":[{"given":"W","family":"Fiskus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S G T","family":"Devaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Horrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Leveque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K N","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,8]]},"reference":[{"key":"BFleu2014340_CR1","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","volume":"149","author":"H Clevers","year":"2012","unstructured":"Clevers H, Nusse R . Wnt\/beta-catenin signaling and disease. Cell 2012; 149: 1192\u20131205.","journal-title":"Cell"},{"key":"BFleu2014340_CR2","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1186624","volume":"327","author":"Y Wang","year":"2010","unstructured":"Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z et al. The Wnt\/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010; 327: 1650\u20131653.","journal-title":"Science"},{"key":"BFleu2014340_CR3","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ccr.2010.10.032","volume":"18","author":"J Yeung","year":"2010","unstructured":"Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D et al. beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010; 18: 606\u2013618.","journal-title":"Cancer Cell"},{"key":"BFleu2014340_CR4","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1182\/blood-2011-03-345165","volume":"118","author":"SW Lane","year":"2011","unstructured":"Lane SW, Wang YJ, Lo Celso C, Ragu C, Bullinger L, Sykes SM et al. Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood 2011; 118: 2849\u20132856.","journal-title":"Blood"},{"key":"BFleu2014340_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1084\/jem.20071875","volume":"205","author":"K Petropoulos","year":"2008","unstructured":"Petropoulos K, Arseni N, Schessl C, Stadler CR, Rawat VP, Deshpande AJ et al. A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med 2008; 205: 515\u2013522.","journal-title":"J Exp Med"},{"key":"BFleu2014340_CR6","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrm3470","volume":"13","author":"C Niehrs","year":"2012","unstructured":"Niehrs C . The complex world of WNT receptor signaling. Nat Rev Mol Cell Biol 2012; 13: 767\u2013779.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFleu2014340_CR7","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1182\/blood-2012-12-473470","volume":"121","author":"W Li","year":"2013","unstructured":"Li W, Hou Y, Ming M, Yu L, Seba A, Qian Z . Apc regulates the function of hematopoietic stem cells largely through beta-catenin-dependent mechanisms. Blood 2013; 121: 4063\u20134072.","journal-title":"Blood"},{"key":"BFleu2014340_CR8","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.cell.2012.05.002","volume":"149","author":"VS Li","year":"2012","unstructured":"Li VS, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP et al. Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell 2012; 149: 1245\u20131256.","journal-title":"Cell"},{"key":"BFleu2014340_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nchembio.453","volume":"6","author":"CA Thorne","year":"2010","unstructured":"Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, Cselenyi CS et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol 2010; 6: 829\u2013836.","journal-title":"Nat Chem Biol"},{"key":"BFleu2014340_CR10","doi-asserted-by":"publisher","first-page":"13507","DOI":"10.1074\/jbc.M109.049411","volume":"285","author":"YN Dimitrova","year":"2010","unstructured":"Dimitrova YN, Li J, Lee YT, Rios-Esteves J, Friedman DB, Choi HJ et al. Direct ubiquitination of beta-catenin by Siah-1 and regulation by the exchange factor TBL1. J Biol Chem 2010; 285: 13507\u201313516.","journal-title":"J Biol Chem"},{"key":"BFleu2014340_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccr.2011.08.016","volume":"20","author":"N Zhang","year":"2011","unstructured":"Zhang N, Wei P, Gong A, Chiu WT, Lee HT, Colman H et al. FoxM1 promotes \u03b2-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 2011; 20: 427\u2013442.","journal-title":"Cancer Cell"},{"key":"BFleu2014340_CR12","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.str.2007.12.021","volume":"16","author":"Y Xing","year":"2008","unstructured":"Xing Y, Takemaru K, Liu J, Berndt JD, Zheng JJ, Moon RT et al. Crystal structure of a full-length beta-catenin. Structure 2008; 16: 478\u2013487.","journal-title":"Structure"},{"key":"BFleu2014340_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.molcel.2006.09.001","volume":"24","author":"J Sampietro","year":"2006","unstructured":"Sampietro J, Dahlberg CL, Cho US, Hinds TR, Kimelman D, Xu W . Crystal structure of a beta-catenin\/BCL9\/Tcf4 complex. Mol Cell 2006; 24: 293\u2013300.","journal-title":"Mol Cell"},{"key":"BFleu2014340_CR14","doi-asserted-by":"publisher","first-page":"28222","DOI":"10.1074\/jbc.M109.045039","volume":"284","author":"R Mo","year":"2009","unstructured":"Mo R, Chew TL, Maher MT, Bellipanni G, Weinberg ES, Gottardi CJ . The terminal region of beta-catenin promotes stability by shielding the Armadillo repeats from the axin-scaffold destruction complex. J Biol Chem 2009; 284: 28222\u201328231.","journal-title":"J Biol Chem"},{"key":"BFleu2014340_CR15","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrm2654","volume":"10","author":"C Mosimann","year":"2009","unstructured":"Mosimann C, Hausmann G, Basler K . Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol 2009; 10: 276\u2013286.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFleu2014340_CR16","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/leu.2009.86","volume":"23","author":"A Valencia","year":"2009","unstructured":"Valencia A, Roman-Gomez J, Cervera J, Such E, Barragan E, Bolufer P et al. Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. Leukemia 2009; 23: 1658\u20131666.","journal-title":"Leukemia"},{"key":"BFleu2014340_CR17","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1038\/sj.leu.2404923","volume":"21","author":"T Kajiguchi","year":"2007","unstructured":"Kajiguchi T, Chung EJ, Lee S, Stine A, Kiyoi H, Naoe T et al. FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells. Leukemia 2007; 21: 2476\u20132484.","journal-title":"Leukemia"},{"key":"BFleu2014340_CR18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1600-0609.2011.01738.x","volume":"88","author":"T Kajiguchi","year":"2012","unstructured":"Kajiguchi T, Katsumi A, Tanizaki R, Kiyoi H, Naoe T . Y654 of beta-catenin is essential for FLT3\/ITD-related tyrosine phosphorylation and nuclear localization of beta-catenin. Eur J Haematol 2012; 88: 314\u2013320.","journal-title":"Eur J Haematol"},{"key":"BFleu2014340_CR19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/leu.2012.221","volume":"27","author":"RG Morgan","year":"2013","unstructured":"Morgan RG, Pearn L, Liddiard K, Pumford SL, Burnett AK, Tonks A et al. \u03b3-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of \u03b2-catenin. Leukemia 2013; 27: 336\u2013343.","journal-title":"Leukemia"},{"issue":"7","key":"BFleu2014340_CR20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"Catriona H.M. Jamieson","year":"2004","unstructured":"Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al N Engl J Med 2004; 351: 657\u2013667.","journal-title":"New England Journal of Medicine"},{"key":"BFleu2014340_CR21","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/sj.emboj.7601485","volume":"26","author":"AM Coluccia","year":"2007","unstructured":"Coluccia AM, Vacca A, Dunach M, Mologni L, Redaelli S, Bustos VH et al. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 2007; 26: 1456\u20131466.","journal-title":"EMBO J"},{"key":"BFleu2014340_CR22","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/1947601910362446","volume":"1","author":"J Jiang","year":"2010","unstructured":"Jiang J, Griffin JD . Wnt\/beta-catenin pathway modulates the sensitivity of the mutant FLT3 receptor kinase inhibitors in a GSK-3beta dependent manner. Genes Cancer 2010; 1: 164\u2013176.","journal-title":"Genes Cancer"},{"key":"BFleu2014340_CR23","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1101\/gad.17421911","volume":"25","author":"JM Perry","year":"2011","unstructured":"Perry JM, He XC, Sugimura R, Grindley JC, Haug JS, Ding S et al. Cooperation between both Wnt\/{beta}-catenin and PTEN\/PI3K\/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion. Genes Dev 2011; 25: 1928\u20131942.","journal-title":"Genes Dev"},{"key":"BFleu2014340_CR24","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/nm.2772","volume":"18","author":"SP Tenbaum","year":"2012","unstructured":"Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S et al. beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012; 18: 892\u2013901.","journal-title":"Nat Med"},{"key":"BFleu2014340_CR25","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1016\/j.ejca.2009.08.003","volume":"45","author":"I Gehrke","year":"2009","unstructured":"Gehrke I, Gandhirajan RK, Kreuzer KA . Targeting the WNT\/beta-catenin\/TCF\/LEF1 axis in solid and haematological cancers: Multiplicity of therapeutic options. Eur J Cancer 2009; 45: 2759\u20132767.","journal-title":"Eur J Cancer"},{"key":"BFleu2014340_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1600-0609.2008.01188.x","volume":"82","author":"KS Minke","year":"2009","unstructured":"Minke KS, Staib P, Puetter A, Gehrke I, Gandhirajan RK, Schlosser A et al. Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. Eur J Haematol 2009; 82: 165\u2013175.","journal-title":"Eur J Haematol"},{"key":"BFleu2014340_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc3419","volume":"13","author":"JN Anastas","year":"2013","unstructured":"Anastas JN, Moon RT . WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13: 11\u201326.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2014340_CR28","doi-asserted-by":"crossref","first-page":"552","DOI":"10.18632\/oncotarget.191","volume":"1","author":"JC Curtin","year":"2010","unstructured":"Curtin JC, Lorenzi MV . Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 2010; 1: 552\u2013566.","journal-title":"Oncotarget"},{"key":"BFleu2014340_CR29","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-09-2943","volume":"16","author":"F Takahashi-Yanaga","year":"2010","unstructured":"Takahashi-Yanaga F, Kahn M . Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010; 16: 3153\u20133162.","journal-title":"Clin Cancer Res"},{"key":"BFleu2014340_CR30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncb1684","volume":"10","author":"J Li","year":"2008","unstructured":"Li J, Wang CY . TBL1-TBLR1 and beta-catenin recruit each other to Wnt target-gene promoter for transcription activation and oncogenesis. Nat Cell Biol 2008; 10: 160\u2013169.","journal-title":"Nat Cell Biol"},{"key":"BFleu2014340_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.molcel.2011.05.027","volume":"43","author":"HK Choi","year":"2011","unstructured":"Choi HK, Choi KC, Yoo JY, Song M, Ko SJ, Kim CH et al. Reversible SUMOylation of TBL1-TBLR1 regulates beta-catenin-mediated Wnt signaling. Mol Cell 2011; 43: 203\u2013216.","journal-title":"Mol Cell"},{"key":"BFleu2014340_CR32","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.molcel.2008.01.020","volume":"29","author":"V Perissi","year":"2008","unstructured":"Perissi V, Scafoglio C, Zhang J, Ohgi KA, Rose DW, Glass CK et al. TBL1 and TBLR1 phosphorylation on regulated gene promoters overcomes dual CtBP and NCoR\/SMRT transcriptional repression checkpoints. Mol Cell 2008; 29: 755\u2013766.","journal-title":"Mol Cell"},{"key":"BFleu2014340_CR33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nsmb.1983","volume":"18","author":"J Oberoi","year":"2011","unstructured":"Oberoi J, Fairall L, Watson PJ, Yang JC, Czimmerer Z, Kampmann T et al. Structural basis for the assembly of the SMRT\/NCoR core transcriptional repression machinery. Nat Struct Mol Biol 2011; 18: 177\u2013184.","journal-title":"Nat Struct Mol Biol"},{"key":"BFleu2014340_CR34","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1128\/MCB.00576-10","volume":"31","author":"S Ramadoss","year":"2011","unstructured":"Ramadoss S, Li J, Ding X, Al Hezaimi K, Wang CY . Transducin beta-like protein 1 recruits nuclear factor kappaB to the target gene promoter for transcriptional activation. Mol Cell Biol 2011; 31: 924\u2013934.","journal-title":"Mol Cell Biol"},{"key":"BFleu2014340_CR35","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood-2004-09-3413","volume":"105","author":"P George","year":"2005","unstructured":"George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005; 105: 1768\u20131776.","journal-title":"Blood"},{"key":"BFleu2014340_CR36","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1182\/blood-2009-03-213496","volume":"114","author":"W Fiskus","year":"2009","unstructured":"Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009; 114: 2733\u20132743.","journal-title":"Blood"},{"key":"BFleu2014340_CR37","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1182\/blood-2010-09-309674","volume":"118","author":"R Balusu","year":"2011","unstructured":"Balusu R, Fiskus W, Rao R, Chong DG, Nalluri S, Mudunuru U et al. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood 2011; 118: 3096\u20133106.","journal-title":"Blood"},{"key":"BFleu2014340_CR38","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1535-7163.MCT-13-0770","volume":"13","author":"W Fiskus","year":"2014","unstructured":"Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther 2014; 13: 1142\u20131154.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2014340_CR39","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/leu.2014.119","volume":"28","author":"W Fiskus","year":"2014","unstructured":"Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SGT, Liu K et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia 2014; 28: 2155\u20132164.","journal-title":"Leukemia"},{"key":"BFleu2014340_CR40","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1158\/0008-5472.CAN-13-2033","volume":"74","author":"W Fiskus","year":"2014","unstructured":"Fiskus W, Saba N, Shen M, Ghias M, Das Gupta S, Chauhan L et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res 2014; 74: 2520\u20132532.","journal-title":"Cancer Res"},{"key":"BFleu2014340_CR41","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","volume":"174","author":"LD Shultz","year":"2005","unstructured":"Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S et al. Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174: 6477\u20136489.","journal-title":"J Immunol"},{"key":"BFleu2014340_CR42","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/leu.2009.143","volume":"23","author":"PV Sanchez","year":"2009","unstructured":"Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, Swider CR et al. A robust xenotransplantation model for acute myeloid leukemia. Leukemia 2009; 23: 2109\u20132117.","journal-title":"Leukemia"},{"key":"BFleu2014340_CR43","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1126\/science.1218370","volume":"336","author":"K Hoffmeyer","year":"2012","unstructured":"Hoffmeyer K, Raggioli A, Rudloff S, Anton R, Hierholzer A, Del Valle I et al. Wnt\/beta-catenin signaling regulates telomerase in stem cells and cancer cells. Science 2012; 336: 1549\u20131554.","journal-title":"Science"},{"key":"BFleu2014340_CR44","doi-asserted-by":"publisher","first-page":"32494","DOI":"10.1074\/jbc.M112.368282","volume":"287","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Toh L, Lau P, Wang X . Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt\/beta-catenin pathway in human cancer. J Biol Chem 2012; 287: 32494\u201332511.","journal-title":"J Biol Chem"},{"key":"BFleu2014340_CR45","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1365-2141.2010.08471.x","volume":"152","author":"EK Siapati","year":"2011","unstructured":"Siapati EK, Papadaki M, Kozaou Z, Rouka E, Michali E, Savvidou I et al. Proliferation and bone marrow engraftment of AML blasts is dependent on \u03b2-catenin signalling. Br J Haematol 2011; 152: 164\u2013174.","journal-title":"Br J Haematol"},{"key":"BFleu2014340_CR46","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1073\/pnas.0900189106","volume":"106","author":"AE Abrahamsson","year":"2009","unstructured":"Abrahamsson AE, Geron I, Gotlib J, Dao KH, Barroga CF, Newton IG et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci 2009; 106: 3925\u20133929.","journal-title":"Proc Natl Acad Sci"},{"key":"BFleu2014340_CR47","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.molcel.2009.11.017","volume":"36","author":"L Goentoro","year":"2009","unstructured":"Goentoro L, Kirschner MW . Evidence that fold-change, and not absolute level, of beta-catenin dictates Wnt signaling. Mol Cell 2009; 36: 872\u2013884.","journal-title":"Mol Cell"},{"key":"BFleu2014340_CR48","doi-asserted-by":"publisher","first-page":"8572","DOI":"10.1158\/0008-5472.CAN-09-1500","volume":"69","author":"FK Noubissi","year":"2009","unstructured":"Noubissi FK, Goswami S, Sanek NA, Kawakami K, Minamoto T, Moser A et al. Wnt signaling stimulates transcriptional outcome of the Hedgehog pathway by stabilizing GLI1 mRNA. Cancer Res 2009; 69: 8572\u20138578.","journal-title":"Cancer Res"},{"key":"BFleu2014340_CR49","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.cell.2012.11.026","volume":"151","author":"J Rosenbluh","year":"2012","unstructured":"Rosenbluh J, Nijhawan D, Cox AJ, Li X, Neal JT, Schafer EJ et al. \u03b2-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 2012; 151: 1457\u20131473.","journal-title":"Cell"},{"key":"BFleu2014340_CR50","doi-asserted-by":"publisher","first-page":"7427","DOI":"10.1128\/MCB.01962-07","volume":"28","author":"T Shimizu","year":"2008","unstructured":"Shimizu T, Kagawa T, Inoue T, Nonaka A, Takada S, Aburatani H et al. Stabilized beta-catenin functions through TCF\/LEF proteins and the Notch\/RBP-Jkappa complex to promote proliferation and suppress differentiation of neural precursor cells. Mol Cell Biol 2008; 28: 7427\u20137441.","journal-title":"Mol Cell Biol"},{"key":"BFleu2014340_CR51","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.cell.2012.12.007","volume":"151","author":"BP Tsai","year":"2012","unstructured":"Tsai BP, Hoverter NP, Waterman ML . Blending hippo and WNT: sharing messengers and regulation. Cell 2012; 151: 1401\u20131403.","journal-title":"Cell"},{"key":"BFleu2014340_CR52","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nm.1913","volume":"15","author":"J Skokowa","year":"2009","unstructured":"Skokowa J, Lan D, Thakur BK, Wang F, Gupta K, Cario G et al. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat Med 2009; 15: 151\u2013158.","journal-title":"Nat Med"},{"key":"BFleu2014340_CR53","doi-asserted-by":"publisher","first-page":"529376","DOI":"10.1155\/2010\/529376","volume":"2010","author":"T Tran","year":"2010","unstructured":"Tran T, Paz P, Velichko S, Cifrese J, Belur P, Yamaguchi KD et al. Interferon\u03b2-1b induces the expression of RGS1 a negative regulator of G-protein signaling. Int J Cell Biol 2010; 2010: 529376.","journal-title":"Int J Cell Biol"},{"key":"BFleu2014340_CR54","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nature12883","volume":"506","author":"A Kode","year":"2014","unstructured":"Kode A, Manavalan JS, Mosialou I, Bhagat G, Rathinam CV, Luo N et al. Leukaemogenesis induced by an activating beta-catenin mutation in osteoblasts. Nature 2014; 506: 240\u2013244.","journal-title":"Nature"},{"key":"BFleu2014340_CR55","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nchembio.313","volume":"6","author":"JE Bradner","year":"2010","unstructured":"Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010; 6: 238\u2013243.","journal-title":"Nat Chem Biol"},{"key":"BFleu2014340_CR56","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","volume":"114","author":"PP Zarrinkar","year":"2009","unstructured":"Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009; 114: 2984\u20132992.","journal-title":"Blood"},{"key":"BFleu2014340_CR57","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1073\/pnas.1320661111","volume":"111","author":"CC Smith","year":"2014","unstructured":"Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK et al. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci USA 2014; 111: 5319\u20135324.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2014340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014340","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:19:02Z","timestamp":1648743542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2014340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,8]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["BFleu2014340"],"URL":"https:\/\/doi.org\/10.1038\/leu.2014.340","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,8]]},"assertion":[{"value":"9 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stephan Horrigan is Chief Scientific Officer of \u03b2-Cat Pharma, Inc. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}